Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Jun / Sitting Down With… The Past: Jane Osbourn
Business & Regulation Profession

Sitting Down With… The Past: Jane Osbourn

We dive into the archive of 2020 for insight and inspiration – this time with Jane Osbourn.

06/18/2024 2 min read

Share

Like many others, Jane Osbourn – CSO of Alchemab and former chair of the UK BioIndustry Association – found science through her desire to understand more about how the world around us works. Her scientific explorations were awarded with an Order of the British Empire and Scrip’s Lifetime Achievement Award for services to drug discovery, development and biotechnology. We discussed her desire for change in the pharma industry, career, and advice for young researchers, among other things.

On the pharma industry:
 

“There should be more focus on identifying drugs based on biological function first; we should be looking at how they interact with disease mechanisms, rather than specifically defined targets. The pharma industry is doing a really great job and has been hugely successful, but we are at a point where target supply in its classic form is becoming limited. We need to look at function first, and how to perform drug screening in a way that will give insight into different areas of biology.”

On her career:
 

“I was a student and post-doc in the 1980s – PCR had just been invented and a revolution was taking place in molecular biology, so it was an exciting time to enter the field. Later, I switched my focus to the emerging area of antibody engineering and applied for a job at Cambridge Antibody Technology (CAT). The technical potential of human antibodies was tempting from an academic perspective, but as soon as I started working in a biotech environment, I realized the full extent of the applications in medicine.”

On young researchers:
 

“I didn’t have a career plan – I followed my passion. My advice is to find your passion and really immerse yourself in it! Become an expert in something early on so that you go through the process of understanding how to get into a subject in depth. If you can do it once, then you will have the confidence to do it again and again in other areas. But wherever you are, keep asking yourself if you’re enjoying it. I had a successful academic career, but I flourished in the biotech environment because there was a sense of pace, shared objectives, and ambition that I loved. I think it is very important to work out your ideal cultural environment and to keep checking that you are meeting your own goals in terms of satisfaction.”

Read the full article, first published in January 2020.

Credit: Interviewee supplied

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Blood Cancer Success Story: Part 1
Profession Drug Discovery
The Blood Cancer Success Story: Part 1

April 9, 2025

7 min read

Lore Gruenbaum tells us about her career spanning big pharma, biotech and now The Leukemia & Lymphoma Society; because there are some goals you can only accomplish in a not-for-profit environment.

Sitting Down With... Moncef Slaoui
Profession Standards & Regulation Bioprocessing - Upstream & Downstream
Sitting Down With... Moncef Slaoui

March 3, 2025

5 min read

From the GSK boardroom to the White House, and now the board of Abzena, the career path of Moncef Slaoui has resulted in billions of doses of lifesaving vaccines. Here he shares his story.

Maintaining Momentum
Profession Advanced Medicine
Maintaining Momentum

February 6, 2025

4 min read

Being part of the cell and gene therapy field is an incredible privilege, according to Frank Mathias, CEO, Oxford Biomedica.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.